Andrejus Parfionovas

Long‐term safety of vedolizumab for inflammatory bowel disease

Edward V. Loftus, Brian G. Feagan, Remo Panaccione et al. · Alimentary Pharmacology & Therapeutics · 2020 · 191 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review

Yngvar Fløisand, Vladimir Lazarević, Johan Maertens et al. · Biology of Blood and Marrow Transplantation · 2018 · 66 citations · Full text

Life Sciences, Hematology, Pharmacotherapy +14

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Yi‐Bin Chen, Nirav N. Shah, Anne S. Renteria et al. · Blood Advances · 2019 · 46 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease

Yngvar Fløisand, Mark A. Schroeder, Patrice Chevallier et al. · Bone Marrow Transplantation · 2021 · 17 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +16

OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study

Séverine Vermeire, J F Colombel, Brian G. Feagan et al. · Journal of Crohn s and Colitis · 2019 · 12 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16